Pfizer’s next play: A vaccine maker and pandemic ‘partner’ to governments

Pfizer Inc.’s COVID-19 vaccine is on track to generate a whopping $26 billion in sales this year, making it the drug maker’s top-selling drug and forging a new path into infectious diseases for the legacy drug maker.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.